Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.46 |
| ▸ | HTT | P42858 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188985 | 0.86 | ALDH1A1 (0.40) | MAPTHTTPOLBNPSR1SMN1; SMN2 | |
| SCHEMBL58073 | 0.84 | MAPT (0.51) | MAPTHTTPOLBNPSR1SMN1; SMN2 | |
| SCHEMBL5179805 | 0.79 | POLB (0.32) | MAPTHTTPOLB | |
| SCHEMBL5189175 | 0.72 | MAPT (0.41) | MAPTHTTPOLBNPSR1SMN1; SMN2 | |
| SCHEMBL29118210 | 0.71 | CSNK2A2 (0.42) | MAPTHTTPOLBNPSR1SMN1; SMN2 | |
| SCHEMBL3192831 | 0.70 | MAPT (0.61) | MAPTHTTPOLBNPSR1SMN1; SMN2 | |
| SCHEMBL31144987 | 0.69 | MAPT (0.41) | MAPTHTTPOLBNPSR1SMN1; SMN2 | |
| SCHEMBL27680372 | 0.67 | MAPT (0.38) | MAPTHTTPOLBNPSR1SMN1; SMN2 | |
| SCHEMBL861476 | 0.64 | MAPT (0.57) | MAPTHTTPOLBNPSR1SMN1; SMN2 | |
| SCHEMBL5179878 | 0.62 | MAPT (0.33) | MAPTHTTPOLBSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082575-A1 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082575-A1 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE | COX4I1, MT-ND4, MT-ND4L | MAPT 4528/4885HTT 2742/4885POLB 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.